With regulatory attention on peptide purity and sourcing higher than ever, knowing how to evaluate a supplier yourself is one of the most useful skills a researcher can have. Here are five warning signs that should make you think twice before ordering.
Peptides Still Aren't Legal: What the FDA Advisory Panel Vote Actually Means
Last month's FDA advisory panel vote on peptide compounding made headlines everywhere — but it's created almost as much confusion as clarity. Here's what actually changed, what hasn't, and what to expect next.
What the Panel Actually Voted On
The panel reviewed seven peptide therapies, including BPC-157, TB-500, and MOTS-c, and voted in favor of six. But a recommendation from an advisory panel is not a change in law — it's still illegal for U.S. pharmacies to compound these substances today. The FDA's own leadership must still review the data and decide whether to act on the panel's recommendation.
What Happens Next
If the FDA moves forward, the most likely path is adding these peptides to the "Category One list," which would let compounding pharmacies begin making them sooner while a longer formal rulemaking process plays out. Industry attorneys and compounding-law experts expect the agency to look for the fastest route available, but timelines remain genuinely uncertain — anywhere from a couple of months to over a year.
Why It's Controversial
FDA staff scientists raised concerns about the lack of published human safety data for all seven peptides and recommended against production, a position the advisory panel didn't fully follow. That disagreement matters: demand for these compounds has outpaced the clinical evidence, and a gray market has filled the gap, often through unvetted "research use only" sourcing.
What This Means for Researchers
Even if the FDA acts quickly, compounded peptides would require a prescription and would come from compounding pharmacies, not routine retail. For researchers working with these compounds now, the fundamentals haven't changed: verify your source, insist on a Certificate of Analysis, and don't assume regulatory attention equals regulatory approval.
A Note on This Guide
This summary reflects reporting from NPR, The Wall Street Journal, and Forbes on the FDA advisory panel's late-July vote, current as of early August 2026. It is provided for general educational purposes and does not constitute legal or medical guidance.

